ArticlePLOS mental health2025
Patient and Prescriber characteristics associated with return to daily-dispense methadone: A multilevel cohort study.
Article in PLOS mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early in the SARS-Cov-2 pandemic, modified clinical guidance recommended the provision of take-home methadone doses for those previously ineligible to facilitate social distancing. Following this change, studies reported improved treatment retention among patients granted expanded access to take-home doses. However, most patients resumed daily dispensed methadone within six months. Factors associated with the return to daily dispensed methadone remain unknown. Therefore, we conducted a population-based cohort study to identify patient and prescriber-related characteristics associated with return to daily dispensed methadone. Our study included all residents of Ontario, Canada who received daily dispensed methadone on March 21, 2020, and were then provided at least one take-home dose between March 22, 2020, and April 21, 2020. Follow-up time was divided into 14-day discrete time intervals. The primary outcome was return to daily dispensed methadone, defined as the first interval where a take-home dose was not dispensed. A multilevel discrete time survival model with a complementary log-log link function and random intercepts across prescribers to account for patient clustering by prescriber was used to approximate cause-specific hazard ratios. Within 26 weeks, 1,675 (58.5%) individuals were reverted to daily dispensed methadone. Person-level variables significantly associated with our primary outcome included occurrence of an emergency department visit during or before the interval of interest (HR = 1.27; 95% CI = 1.05, 1.55) and missed methadone dose(s) in the interval prior (HR = 1.59; 95% CI = 1.44, 1.76). Lastly, patients prescribed methadone by a high-volume (top 20th percentile) opioid agonist treatment prescriber had an increased hazard of return to daily dispensed methadone compared to those prescribed methadone by a low-volume (50th percentile) prescriber (HR = 1.44; 95% CI = 1.14, 1.83). While patient characteristics that may indicate clinical instability, such as recent history of missed methadone dose(s) were associated with return to daily dispensed methadone, prescriber OAT client volume was also be associated this outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.